Journal Article Summary
The article examines the continuation rates of the etonogestrel (ENG) contraceptive implant among women who started using it during an emergency contraception (EC) visit. This topic is significant because it addresses the growing use of emergency contraception and the importance of providing effective ongoing contraceptive options immediately after an unprotected sexual encounter. Understanding how well women continue using the ENG implant after initiating it with EC can help inform family planning practices and improve contraceptive care.
The study involved 160 women aged 18 to 35 who sought emergency contraception at four family planning clinics in Utah between February 2021 and April 2023. After one year, 82.5% of the participants were accounted for, with 59.8% still using the ENG implant and 40.2% having discontinued it. The research found that privately insured women were more likely to stop using the implant compared to those without insurance. Satisfaction levels also varied, with a higher percentage of those who continued using the implant reporting satisfaction compared to those who discontinued.
Limitations of the study include a relatively small sample size and some participants not completing follow-up surveys, which could affect the results. Additionally, while the study highlights the importance of providing ongoing contraception at EC visits, it does not detail side effects experienced by those who continued using the implant. Patients should discuss their contraceptive options and any concerns about side effects or satisfaction with their healthcare provider to make informed decisions about their reproductive health.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Gawron Lori M., Sexsmith Corinne D., Carter Gentry, Kaiser Jennifer E., Woodcock Alexandra, Turok David K.. One-year continuation of the etonogestrel contraceptive implant initiated with oral emergency contraception. Contraception 2025. DOI: 10.1016/j.contraception.2025.110938. PMID: 40345367. PMCID: PMC12543269.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
